局灶节段性肾小球硬化中蛋白尿减少与肾脏生存的关系
该研究基于一项比较环孢素与霉酚酸酯联合地塞米松治疗类固醇抵抗型FSGS的随机试验,纳入138例患者,分析治疗26周内蛋白尿下降与后续eGFR变化及肾脏衰竭或死亡复合结局的关系。结果显示,log尿蛋白肌酐比每降低1单位,eGFR每年增加3.90 mL/min/1.73m²(95%CI 2.01-5.79),复合结局风险比为0.23(95%CI 0.12-0.44)。
要点
- 治疗26周内蛋白尿下降与后续eGFR斜率改善显著相关。
- log尿蛋白肌酐比每降低1单位,eGFR每年增加3.90 mL/min/1.73m²。
- 蛋白尿下降与肾脏衰竭或死亡复合结局风险降低相关(HR 0.23)。
核心结论
- 在类固醇抵抗型FSGS患者中,治疗后的蛋白尿减少与更好的肾脏生存相关。
- 蛋白尿减少可作为保留肾功能的潜在替代指标,值得进一步评估。
研究设计与样本
- 临床试验参与者的队列分析,纳入138例类固醇抵抗型FSGS患者(原试验共192例)。
- 原试验随机比较环孢素与霉酚酸酯联合地塞米松治疗。
主要发现
- 26周内蛋白尿变化与eGFR斜率显著相关:log尿蛋白肌酐比每降低1单位,eGFR每年增加3.90 mL/min/1.73m²(95%CI 2.01-5.79)。
- 调整完全缓解后该差异仍显著。
- 时变蛋白尿与复合结局相关:log尿蛋白肌酐比每降低1单位,HR为0.23(95%CI 0.12-0.44)。
临床怎么用
- 在类固醇抵抗型FSGS患者中,治疗期间监测蛋白尿下降有助于评估肾脏预后。
- 蛋白尿减少可作为未来临床试验设计的潜在替代终点。
局限性
- 仅限类固醇抵抗型FSGS患者,随访最长5年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Remission of proteinuria has been shown to be associated with lower rates of kidney disease progression among people with focal segmental glomerulosclerosis (FSGS). The goal of this study was to evaluate whether reductions in proteinuria after treatment are associated with greater kidney survival. STUDY DESIGN: Cohort analysis of clinical trial participants. SETTING & PARTICIPANTS: Patients with steroid-resistant FSGS enrolled in a randomized treatment trial that compared cyclosporine with mycophenolate mofetil plus dexamethasone. PREDICTORS: Reduction in proteinuria measured during 26 weeks after initiating treatment. OUTCOMES: Repeated assessments of estimated glomerular filtration rate (eGFR) and time to a composite outcome of kidney failure or death assessed between 26 weeks and 54 months after randomization. ANALYTICAL APPROACH: Multivariable linear mixed-effects models with participant-specific slope and intercept to estimate the association of change in proteinuria over 26 weeks while receiving treatment with the subsequent slope of change in eGFR. Multivariable time-varying Cox proportional hazards models were used to estimate the association of changes in proteinuria with time to the composite outcome. RESULTS: 138 of 192 trial participants were included. Changes in proteinuria over 26 weeks were significantly related to eGFR slope. A 1-unit reduction in log-transformed urinary protein-creatinine ratio was associated with a 3.90mL/min/1.73m2 per year increase in eGFR (95% CI, 2.01-5.79). This difference remained significant after adjusting for complete remission. There was an analogous relationship between time-varying proteinuria and time to the composite outcome: the HR per 1-unit reduction in log-transformed urinary protein-creatinine ratio was 0.23 (95% CI, 0.12-0.44). LIMITATIONS: Limited to individuals with steroid-resistant FSGS followed up for a maximum of 5 years. CONCLUSIONS: These findings provide evidence for the benefit of urinary protein reduction in FSGS. Reductions in proteinuria warrant further evaluation as a potential surrogate for preservation of kidney function that may inform the design of future clinical trials.
引用
- Troost JP, Trachtman H, Spino C, et al. Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis. Am J Kidney Dis. 2020. PMID: 32791086. doi:10.1053/j.ajkd.2020.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。